SynthesisMolecular biology reports2012
DNMT3B polymorphisms and cancer risk: a meta analysis of 24 case-control studies.
Synthesis in Molecular biology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- DNMT1, DNMT3A and DNMT3B Polymorphisms Associated With Gastric Cancer Risk: A Systematic Review and Meta-analysis.EBioMedicine · 2016Pooled it
- Systematic evaluation of cancer risk associated with DNMT3B polymorphisms.Journal of cancer research and clinical oncology · 2015Pooled it
- Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala Is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies.Diabetes care · 2012Pooled it
- Article
- Investigation of the DNMT3B -579 G>T Promoter Polymorphism in Patients with Colorectal Cancer in an Azerbaijani Population.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- DNMT3B-579G>T (rs1569686G>T) polymorphism and the risk of multiple sclerosis in a subset of Iranian population.Iranian journal of neurology · 2019Article
- DNMT3B -579 G>T Promoter Polymorphism and the Risk of Gastric Cancer in the West of Iran.Journal of gastrointestinal cancer · 2018Article
- DNMT3B Functions: Novel Insights From Human Disease.Frontiers in cell and developmental biology · 2018Review
- Quantification of gene-specific methylation of DNMT3B and MTHFR using sequenom EpiTYPER®.Data in brief · 2016Article
- Polymorphism of DNA Methyltransferase 3b and Association with Development and Prognosis in Gastric Cancer.PloS one · 2015Article
- The genetics of folate metabolism and maternal risk of birth of a child with Down syndrome and associated congenital heart defects.Frontiers in genetics · 2015Review
- Association of DNMT3B -283 T > C and -579 G > T polymorphisms with decreased cancer risk: evidence from a meta-analysis.International journal of clinical and experimental medicine · 2015Article
- DNMT3B C46359T and SHMT1 C1420T polymorphisms in the folate pathway in carcinogenesis of head and neck.Molecular biology reports · 2014Article
- Promoter polymorphisms of DNA methyltransferase 3B and risk of hepatocellular carcinoma.Biomedical reports · 2013Article
- Association of the DNMT3B -579G>T polymorphism with risk of thymomas in patients with myasthenia gravis.PloS one · 2013Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The association between polymorphism of DNA methyltransferases 3B and cancer risk has been widely studied recently, and no consensus conclusion is available up to now. We perform a comprehensive search using the databases of Medline, ISI Web of Knowledge and Embase. The odds ratio (OR) and its 95% confidence interval (95% CI) are used to investigate the strength of the association. A total of 24 case-control studies with 15,647 individuals are included in this meta-analysis. For -149C > T (17 studies, 5229 cases and 6910 controls), no evidence indicate that individuals carrying the variant genotypes (CC + CT), relative to those carrying the wild homozygote TT genotype, have an increased risk of cancer (OR = 1.03; 95% CI = 0.84-1.26; P = 0.76). Similarly, no cancer risk is found in the subgroup analyses. For -579G > T (11 studies, 3513 cases and 3714 controls), significantly decreased risks of cancer are observed, and the ORs (95% CI) are 0.70 (0.56-0.87) for GT versus TT, 0.70 (0.57-0.85) for GG + GT versus TT and 0.76 (0.63-0.93) for G-allele versus T-allele, respectively. Subgroup analyses stratified by ethnicity and types of cancer are also performed, and results indicated that -579G > C polymorphism is associated with risk of cancer in Asians [0.68 (0.53-0.87) for GT vs. TT] but not in Europeans [0.82 (0.63-1.07) for GT vs. TT]. We also observe that the -579G is associated with decreased risk of colorectal cancer [0.49(0.38-0.62) for GT vs. TT]. More studies with larger sample size were needed to provide more precise evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.